Eric Lefkofsky, the co-founder of Tempus Labs in Chicago, has been identified by the National Cancer Institute by starting up one of the most all-inclusive cancer centers in the United States. Founded only three years ago, the services Tempus now provides are vastly broad and astounding, including medical testing such as: sequencing of patients’ tumors and germline DNA, liquid biopsy of cell-free DNA, RNA sequencing of tumors, immune system characterization of tumors and patients, organoid cultures of tumor cells with drug testing, containment of information with electronic medical records, and pathology and medical imaging. The data given from these medical tests allows physicians to utilize sound decision-making when it comes to caring for their patients (Harris, 2018).
Tempus Labs has earned a reputation as providing the most revolutionary technology by offering technologies such as gene therapy and gene editing.
Gene therapy and gene editing can be used to cure diseases that were originally thought to be untreatable in genetic diseases such as Hunter syndrome. Lefkofsky and Tempus Labs are also responsible for designing pathogen sequencing technology, which allows for accelerated sequencing of pathogen genomes. This technology is vital for the deterrence of disastrous disease outbreaks and can also be used to trigger expedited public health responses. Eric Lefkofsky and Tempus Labs are also experimenting with Chimeric antigen receptor T (CAR-T) Immunotherapy.
Two separate pharmaceuticals fall under the CAR-T Immunotherapy umbrella: Yescarta and Kymriah. These two drugs are altering the treatment of hematologic malignancies in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia. Tempus Labs has also invested in a blood pressure smart watch that reads blood pressure by briefly occluding the radial artery (Harris, 2018).
In addition to co-founding Tempus Labs, Lefkofsky also co-founds the Lefkofsky Family Foundation which serves to enhance lives by elevating the importance of education, arts and culture, human rights, and medicine. Lefkofsky is also an accomplished author and an adjunct professorship at the University of Chicago’s Booth School of Business (Harris, 2018). It is clear from Lefkofsky’s dedication to a diversified group of communities that he is the perfect example of what a true philanthropist looks like.
Harris, Brian. (2018, January). Eric Lefkofsky’s Tempus Labs Uses Big Data Analytics to Revolutionize Cancer Medicine. Retrieved from